NCT05339685 - A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 20, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Breast Cancer

Interventions

DRUG

BL-M02D1

Administration by intravenous infusion

Trial Locations (10)

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou

The First Affiliated Hospital of Bengbu Medical College, Bengbu

Zhujiang Hospital of Southern Medical University, Guangzhou

The Second Affiliated Hospital of Guilin Medical University, Guilin

Hubei Cancer Hospital, Wuhan

Renmin Hospital of Wuhan University, Wuhan

Zhongnan Hospital of Wuhan University, Wuhan

Yueyang People's Hospital, Yueyang

The First Affiliated Hospital of Jilin University, Changchun

Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors

collaborator

SystImmune Inc.

INDUSTRY

collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY